Medical Patent News

RSS

AstraZeneca receives six months pediatric exclusivity patent extension for ARIMIDEX (anastrozole)

AstraZeneca has announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX (anastrozole) for its licensed breast cancer indications until June 2010.

2 Dec 2007

Vermillion issued U.S. patent for method to aid diagnosis of nephrotic syndrome

Vermillion, Inc. has announced that the United States Patent Office (USPTO) has issued Vermillion U.S. Patent No. 7,297,556 for aiding diagnosis of nephrotic syndrome, a kidney disorder marked by very high or low levels of protein in the urine, which results in bodily swelling and high cholesterol.

29 Nov 2007

Cambridge Research and Instrumentation receives US patent for spectral imaging of deep tissue

Cambridge Research & Instrumentation (CRi) has announced that the United States Patent Office has issued a notice of allowance for their patent application number 10/669,101, for Spectral Imaging of Deep Tissue.

29 Nov 2007

Oncolytics Biotech issued new U.S. patent - reovirus for the treatment of neoplasia

Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia."

27 Nov 2007

Isotechnika granted Norwegian patent for lead immunosuppressive drug

Isotechnika Inc. has announced that the Company has been issued Norwegian Patent No. 324042 for its lead immunosuppressive drug, ISA247.

27 Nov 2007

Barr Pharmaceuticals confirms patent challenge of Focalin XR

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed for Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules, 5mg, 10mg, 15mg & 20mg. Focalin XR is manufactured for the U.S. for Novartis Pharmaceuticals Corporation by Elan Holdings Inc.

21 Nov 2007

Affiris GmbH granted a Europe-wide patent for key elements of its Alzheimer's vaccine

As a result, the company has exclusive rights of use to the peptide sequences for an innovative approach to vaccine development. The tolerability of the first Affiris vaccine, AFFITOPE AD01, is currently being tested as part of a phase I clinical trial. The lead investor in the company, MIG-Fonds, is extremely satisfied with the expanding patent portfolio of Affiris GmbH.

21 Nov 2007

Nanogen reissued patent for diagnosis of chronic congestive heart failure

Nanogen, Inc. has announced that it has been granted U.S. Patent No. RE39,816, which is a reissue of United States Patent No. 6,461,828, titled, "Conjunctive Analysis of Biological Marker Expression For Predicting Cardiac Mortality".

19 Nov 2007

Morphotek issued new U.S patent for method to enhance the affinity of monoclonal antibodies

Morphotek, Inc., a subsidiary of Eisai Co., Ltd. has announced the issuance of United States Patent No. 7,235,643 B2 (the "643" patent).

19 Nov 2007

Avicena receives U.S. patent for compounds to treat Lou Gehrig's disease

Avicena Group, Inc. has announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent #7,285,573 for the use of the Company's proprietary drug candidates for the treatment of amyotrophic lateral sclerosis ("ALS" or "Lou Gehrig's Disease").

14 Nov 2007

Foamix issued cosmetic and pharmaceutical foam patent approvals

Foamix Ltd., a leading developer of topical foam products for dermatology, gynecology and skin-care, has been awarded a New Zealand patent and four South African patents related to the Company's proprietary foam technology.

14 Nov 2007

CellCyte Genetics receives patent on stem cell delivery method

CellCyte Genetics Corporation has announced that is has received notice of the issuance of a U.S. patent (U.S. Patent No. 7,282,222) for its unique methods and compositions approach to deliver and direct stem cells to target organs in the body.

13 Nov 2007

Microcarrier patent to be auctioned

Sedum Laboratories, Inc., formerly of Mansfield, Mass., is auctioning its U.S. Patent #6,645,525 titled "Ionically Formulated Biomolecule Microcarriers."

6 Nov 2007

Barr confirms patent challenge of Ritalin LA

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Novartis Pharmaceuticals Corporation in connection with its Ritalin LA (methylphenidate hydrochloride) extended-release capsules, 10mg, 20mg, 30mg and 40mg.

5 Nov 2007

Boston Scientific announces verdict in Cordis patent case

Boston Scientific Corporation has announced that a jury in U.S. District Court in San Francisco has found that Boston Scientific infringes a patent of Cordis Corporation, a subsidiary of Johnson & Johnson, under the doctrine of equivalents.

1 Nov 2007

Nventa Biopharmaceuticals receives new U.S. patent

Nventa Biopharmaceuticals Corporation has announced that the U.S. Patent and Trademark Office has issued Patent Number 7,262,014 to Nventa covering compositions and methods for inducing or enhancing immune responses to a human papillomavirus (HPV) antigen with or without the use of an adjuvant.

29 Oct 2007

Gene screen patent brings 2007 Deal of Distinction Award to UChicagoTech

UChicagoTech, the University of Chicago's Office of Technology and Intellectual Property, has received a 2007 Deal of Distinction Award from the Licensing Executives Society of U.S.A. and Canada.

29 Oct 2007

Sigma-Aldrich and Oxford BioMedica win key ruling in Open Biosystems patent case

Sigma-Aldrich and Oxford BioMedica have announced that they received a key order confirming the strength and validity of intellectual property owned by Oxford BioMedica and licensed exclusively in the research field to Sigma-Aldrich.

25 Oct 2007

Illumina named as defendant in patent infringement suits

Illumina, Inc. (NASDAQ:ILMN) released the following statement by Jay Flatley, its Chief Executive Officer, in response to new patent infringement suits filed yesterday by Affymetrix in Delaware, the United Kingdom and Germany. As of this time, Illumina has yet to be served with these suits.

From Illumina, Inc. 25 Oct 2007

Mylan settles Paroxetine Hydrochloride patent license with GlaxoSmithKline

Mylan Inc. has announced that it and its subsidiary Mylan Pharmaceuticals Inc. have entered into a patent license and settlement agreement with GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, the generic version of GSK's Paxil CR.

24 Oct 2007